Page last updated: 2024-09-04

dx 8951 and Carcinoma, Anaplastic

dx 8951 has been researched along with Carcinoma, Anaplastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Colucci, P; Cristofanilli, M; DeJager, R; Duggal, A; Esteva, FJ; Hortobagyi, GN; Rivera, E; Royce, M; Valero, V	1

Trials

1 trial(s) available for dx 8951 and Carcinoma, Anaplastic

Article	Year
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer, 2003, Sep-01, Volume: 98, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome	2003

Article

Year

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.

Cancer, 2003, Sep-01, Volume: 98, Issue:5

Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome

2003